NEOGAP Therapeutics AB

📍 Stockholm, Sweden🗓 Founded 2016👥 24 employees💰 Last funded Dec 2021
Pharmaceutical Manufacturing🌐 neogap.se
Website LinkedIn
NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden.  Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2016
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Sweden
2
Frequently asked questions
Who invested in NEOGAP Therapeutics AB?
NEOGAP Therapeutics AB has 2 investors on record on gritt.io, 2 mid-stage.
When did NEOGAP Therapeutics AB last raise funding?
The most recent investment in NEOGAP Therapeutics AB recorded on gritt.io was in December 2021.
When was NEOGAP Therapeutics AB founded?
NEOGAP Therapeutics AB was founded in 2016.
What industry is NEOGAP Therapeutics AB in?
NEOGAP Therapeutics AB operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is NEOGAP Therapeutics AB based?
NEOGAP Therapeutics AB is headquartered in Stockholm, Sweden.